Orca T News Today

In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.

The use of Orca-T with myeloablative chemotherapy conditioning had comparable safety and efficacy to that of standard allogeneic transplant in younger and older patients with hematologic malignancies, according to data from a phase 1b study.